File #: 19-00482    Version: 1
Type: Agenda Item Status: Passed
File created: 5/24/2019 In control: BOARD OF SUPERVISORS
On agenda: 6/4/2019 Final action: 6/4/2019
Title: Consider recommendations regarding a Request for Waiver of Competition in the purchase of pharmaceuticals, laboratory, and medical supplies, as follows: a) Approve and authorize the Chief Procurement Officer, the County's Purchasing Agent, to procure from the vendors listed in Table 1 pharmaceuticals, laboratory, and medical supplies, without a competitive bid up to an amount of $817,000.00 for each Fiscal Year (FY) 2019-2020, 2020-2021, and 2021-2022 with a total amount not to exceed $2,451,000.00 over the three-year period. Hardy Media is a local vendor; all other vendors are not local vendors; b) Approve, ratify, and authorize the Chief Procurement Officer, the County's Purchasing Agent, to increase the previously approved Purchase Order Agreement No. BL02574, with Glaxo/Smith Klein by $10,000.00 for a total amount not to exceed $35,000.00 for FY 2018-2019 without requiring a competitive bid; and c) Find that the proposed actions do not constitute a "Project" within the meaning o...
Sponsors: PUBLIC HEALTH DEPARTMENT
Attachments: 1. Board Letter, 2. Minute Order

Title

Consider recommendations regarding a Request for Waiver of Competition in the purchase of pharmaceuticals, laboratory, and medical supplies, as follows:

 

a) Approve and authorize the Chief Procurement Officer, the County’s Purchasing Agent, to procure from the vendors listed in Table 1 pharmaceuticals, laboratory, and medical supplies, without a competitive bid up to an amount of $817,000.00 for each Fiscal Year (FY) 2019-2020, 2020-2021, and 2021-2022 with a total amount not to exceed $2,451,000.00 over the three-year period. Hardy Media is a local vendor; all other vendors are not local vendors;

 

b) Approve, ratify, and authorize the Chief Procurement Officer, the County’s Purchasing Agent, to increase the previously approved Purchase Order Agreement No. BL02574, with Glaxo/Smith Klein by $10,000.00 for a total amount not to exceed $35,000.00 for FY 2018-2019 without requiring a competitive bid; and

 

c) Find that the proposed actions do not constitute a “Project” within the meaning of California Environmental Quality Act (CEQA), pursuant to Section 15378(b)(4) of the CEQA Guidelines, because they consist of the creation of government funding mechanisms or other government fiscal activities, which do not involve any commitment to any specific project which may result in a potentially significant impact on the environment.